HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection
Troy J Kemp, Allan Hildesheim, Mahboobeh Safaeian, Joseph G Dauner, Yuanji Pan, Carolina Porras, John T Schiller, Douglas R Lowy, Rolando Herrero, Ligia A Pinto, Troy J Kemp, Allan Hildesheim, Mahboobeh Safaeian, Joseph G Dauner, Yuanji Pan, Carolina Porras, John T Schiller, Douglas R Lowy, Rolando Herrero, Ligia A Pinto
Abstract
Human papillomavirus (HPV) L1 VLP-based vaccines are protective against HPV vaccine-related types; however, the correlates of protection have not been defined. We observed that vaccination with Cervarix™ induced cross-neutralizing antibodies for HPV types for which evidence of vaccine efficacy has been demonstrated (HPV31/45) but not for other types (HPV52/58). In addition, HPV31/45 cross-neutralizing titers showed a significant increase with number of doses (HPV31, p<0.001; HPV45, p<0.001) and correlated with HPV16/18 neutralizing titers, respectively. These findings raise the possibility that cross-neutralizing antibodies are effectors of cross-protection observed for the HPV16/18 vaccine.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Source: PubMed